Imunon, Inc. – NASDAQ:CLSN

Add to watchlist

$1.96

Market closed

Open in about 6 hours

-13.65%

month

+5.95%

quarter

+104.17%

year

Market Cap	14.47M
Enterprise value	N/A

P/E	-0.49
EV/Sales	-17.84
EV/EBITDA	0.32
Price/Sales	36.24
Price/Book	0.28
PEG ratio	N/A
EPS	-2.02

Revenue	N/A
EBITDA	-19.07M
Income	-18.85M
Revenue Q/Q	N/A
Revenue Y/Y	1780.19%

Profit margin	-6973.1%
Oper. margin	-5966.05%
Gross margin	0%
EBIT margin	-5966.05%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Imunon, Inc. (NASDAQ:CLSN): Profit margin
Jun 2023	0	-5.55M
Sep 2023	0	-3.47M
Dec 2023	7.05M	-4.88M	-69.33%
Mar 2024	0	-4.92M

Imunon, Inc. (NASDAQ:CLSN): Earnings per share (EPS)
2022-05-16	-0.99	-1.82
2022-08-15	-1.12	-0.87

Imunon, Inc. (NASDAQ:CLSN): Debt to assets
Jun 2023	28721694	7.20M	25.09%
Sep 2023	24654428	6.58M	26.7%
Dec 2023	21918069	8.53M	38.92%
Mar 2024	14324768	5.82M	40.66%

Imunon, Inc. (NASDAQ:CLSN): Cash Flow
Jun 2023	-6.69M	3.12M	-6.22M
Sep 2023	-4.47M	10.66M	78.26K
Dec 2023	-3.77M	-3.30M	30.24K
Mar 2024	-5.87M	2.38M	0

Imunon alternative data

Imunon, Inc. (NASDAQ:CLSN): Employee count
Aug 2023	29
Sep 2023	29
Oct 2023	29
Nov 2023	29
Dec 2023	29
Jan 2024	29
Feb 2024	29
Mar 2024	29
Apr 2024	29
May 2024	29
Jun 2024	29
Jul 2024	29

Imunon
Hedge Funds Holdings Q2 2022

78.60% +33.61%

of CLSN is owned by hedge funds

15 -2

hedge funds hold CLSN stock

918.35K +392.72K

shares is hold by hedge funds

CLSN hedge funds holdings changes

Imunon, Inc. (NASDAQ:CLSN): Insider trades (number of shares)
Period	Buy	Sel
May 2021	5000	0
Oct 2021	20000	0
Mar 2022	2000	0
Apr 2022	9000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	12 Apr 2022	TARDUGNO MICHAEL H director, officer..	Celsion Corporation Common Stock	4,000	$3.53	$14,128
Purchase	12 Apr 2022	TARDUGNO MICHAEL H director, officer..	Celsion Corporation Common Stock	4,000	$3.53	$14,128
Purchase	8 Apr 2022	FRITZ FREDERICK J. director director	Celsion Corporation Common Stock	5,000	$4.05	$20,250
Purchase	2 Mar 2022	FRITZ FREDERICK J. director director	Celsion Corporation Common Stock	2,000	$4.69	$9,372
Purchase	7 Oct 2021	FRITZ FREDERICK J. director director	Celsion Corporation Common Stock	20,000	$0.88	$17,600
Purchase	17 May 2021	BRAUN DONALD P director director	Celsion Corporation Common Stock	5,000	$1.07	$5,350
Purchase	28 Feb 2020	MARTINEZ ALBERTO R JR director director	Celsion Corporation Common Stock	5,000	$0.9	$4,500
Purchase	20 Nov 2019	MARTINEZ ALBERTO R JR director director	Celsion Corporation Common Stock	6,000	$1.42	$8,520
Purchase	6 Nov 2019	FRITZ FREDERICK J. director director	Celsion Corporation Common Stock	10,000	$1.39	$13,880
Purchase	4 Nov 2019	MARTINEZ ALBERTO R JR director director	Celsion Corporation Common Stock	4,000	$1.61	$6,440

Imunon
Earnings Call Transcripts

Quarter	Transcript
Q2 2022 15 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 16 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 31 Mar 2022	Q4 2021 Earnings Call Transcript
Q3 2021 15 Nov 2021	Q3 2021 Earnings Call Transcript

CLSN earnings call transcripts

Imunon
Executives

Insider	Age	Compensation
Mr. Michael H. Tardugno (1951) Executive Chairman, Pres & Chief Executive Officer	74	$1,000,000
Dr. Nicholas Borys (1959) Executive Vice President & Chief Medical Officer	66	$582,240
Mr. Jeffrey W. Church CPA, CPA (1957) Chief Financial Officer, Executive Vice President & Corporation Sec.	68	$522,620
Dr. Khursheed Anwer M.B.A., Ph.D. (1960) Executive Vice President & Chief Scientific Officer	65	$484,750

Imunon
Latest News

Monday, 19 September 2022
16:30	Celsion Corporation Announces Company Name Change to Imunon, Inc.	globenewswire.com
Thursday, 15 September 2022
08:30	Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer	globenewswire.com
Monday, 12 September 2022
18:30	Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.	GlobeNewsWire
Wednesday, 7 September 2022
09:15	Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference	GlobeNewsWire
Monday, 15 August 2022
15:31	Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Monday, 8 August 2022
08:30	Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022	GlobeNewsWire
Monday, 16 May 2022
15:26	Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Monday, 9 May 2022
08:30	Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022	GlobeNewsWire
Wednesday, 6 April 2022
09:39	Why Celsion Shares Are Pulling Back Today	Benzinga
08:30	Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial	GlobeNewsWire
Tuesday, 5 April 2022
15:17	Why Celsion Stock Is Surging Today	Benzinga
Thursday, 31 March 2022
13:41	Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 24 March 2022
09:00	Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022	GlobeNewsWire
Tuesday, 1 March 2022
08:04	Celsion (CLSN) Stock: 1-For-15 Reverse Split Goes Into Effect	Pulse2
Monday, 29 November 2021
08:30	Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit	GlobeNewsWire
Monday, 15 November 2021
14:41	Celsion Corporation (CLSN) CEO Michael Tardugno on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Tuesday, 9 November 2021
09:00	Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021	GlobeNewsWire
Friday, 15 October 2021
09:00	Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress	GlobeNewsWire
Tuesday, 12 October 2021
11:20	CLSN Stock: Why It Increased This Week	Pulse2
09:00	Celsion Corporation Announces Oral Presentation at International Vaccines Congress	GlobeNewsWire
Monday, 11 October 2021
09:00	Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews	GlobeNewsWire
Friday, 17 September 2021
09:00	Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion's DNA-based Vaccine	GlobeNewsWire
Friday, 10 September 2021
15:27	Hot Penny Stocks to Add to Your September Watchlist	PennyStocks
Friday, 3 September 2021
13:45	Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies	Zacks Investment Research
Thursday, 19 August 2021
17:15	Hot Penny Stocks to Watch Right Now, Have You Heard of These 3?	PennyStocks

Frequently Asked Questions (FAQ)

What's the price of Imunon stock today?

One share of Imunon stock can currently be purchased for approximately $1.96.
When is Imunon's next earnings date?

Unfortunately, Imunon's (CLSN) next earnings date is currently unknown.
Does Imunon pay dividends?

No, Imunon does not pay dividends.
How much money does Imunon make?

Imunon has a market capitalization of 14.47M. Imunon made a loss 19.51M US dollars in net income (profit) last year or -$0.87 on an earnings per share basis.
What is Imunon's stock symbol?

Imunon, Inc. is traded on the NASDAQ under the ticker symbol "CLSN".
What is Imunon's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Imunon?

Shares of Imunon can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Imunon's key executives?
Imunon's management team includes the following people:
- Mr. Michael H. Tardugno Executive Chairman, Pres & Chief Executive Officer(age: 74, pay: $1,000,000)
- Dr. Nicholas Borys Executive Vice President & Chief Medical Officer(age: 66, pay: $582,240)
- Mr. Jeffrey W. Church CPA, CPA Chief Financial Officer, Executive Vice President & Corporation Sec.(age: 68, pay: $522,620)
- Dr. Khursheed Anwer M.B.A., Ph.D. Executive Vice President & Chief Scientific Officer(age: 65, pay: $484,750)
How many employees does Imunon have?

As Jul 2024, Imunon employs 29 workers.
When Imunon went public?

Imunon, Inc. is publicly traded company for more then 31 years since IPO on 27 Oct 1993.
What is Imunon's official website?

The official website for Imunon is celsion.com.
Where are Imunon's headquarters?

Imunon is headquartered at 997 Lenox Dr Ste 100, Lawrence Township, NEW JERSEY.
How can i contact Imunon?

Imunon's mailing address is 997 Lenox Dr Ste 100, Lawrence Township, NEW JERSEY and company can be reached via phone at +1 609 896 9100.

Imunon, Inc.

celsion.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

+1 609 896 9100

997 Lenox Dr Ste 100
Lawrence Township, NEW JERSEY 08648

CIK: 0000749647
ISIN: US15117N6022
CUSIP: 15117N602